Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study

Abstract

Although immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain. This real‐world study assessed the efficacy and safety of second‐line immunotherapy in ES‐SCLC patients using propensity score matching (PSM).